ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE
Clinical trials for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE explained in plain language.
Never miss a new study
Get alerted when new ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE trials appear
Sign up with your email to follow new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy shows promise against hard-to-treat t-cell lymphoma
Disease control OngoingThis study tested a combination of a targeted drug (brentuximab vedotin) and chemotherapy in 48 adults with a rare, aggressive lymphoma called CD30-positive peripheral T-cell lymphoma. The goal was to see how well the treatment shrinks tumors and what side effects occur. Particip…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 09:51 UTC
-
Cancer-killing virus plus immune booster shows promise for rare skin tumors
Disease control OngoingThis study tests a two-step treatment for people with rare skin cancers or certain lymphomas that haven't responded to standard care. First, patients receive a virus-based therapy (talimogene laherparepvec) that infects and kills tumor cells. Then, they also get an immunotherapy …
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC